ReviewInflammation and regeneration2025
Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors.
Review in Inflammation and regeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.Reviews in medical virology · 2026Review
- Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatment.Oncology reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-T cell therapy is now considered a mainstay treatment for certain hematologic malignancies, as evidenced by several products that have gained marketing authorization from regulatory authorities worldwide. Despite the undeniable successes of this treatment in certain blood cancers, its effectiveness in solid tumors remains unsatisfactory. This limited efficacy is attributed to several factors, including low trafficking and poor infiltration of CAR-T cells into the tumor bed, antigen heterogeneity, the risk of on-target off-tumor toxicities, immunosuppressive tumor microenvironment, and intrinsic resistance mechanisms in tumor cells. Advances in gene editing platforms, notably CRISPR/Cas9 and its derivative novel technologies, have created opportunities to overcome the existing hurdles of CAR-T cell therapy in solid tumors. Gene editing can be harnessed to disrupt, correct, activate, repress intended genes, and precisely integrate transgenes at predefined loci. Multiplex genome editing using the CRISPR system enables the simultaneous targeting of multiple genes to induce desired changes in cellular behavior, aiming to improve the efficacy and safety profile of CAR-T cell therapy. This review comprehensively examines how gene editing technology is leveraged to enhance CAR-T cell therapy against solid tumors. In this regard, after an overview of various applications of gene editing in CAR-T cell therapy of solid tumors, clinical trials of genome-edited CAR-T cells in solid tumors are discussed to provide a comprehensive perspective regarding the current state of genome-edited CAR-T cell therapy in solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.